Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:investigational_drug
gptkb:drug |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
1627709-88-5
|
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
Phase II |
| gptkbp:developedBy |
Antengene Corporation
|
| gptkbp:indication |
solid tumors
hematologic malignancies |
| gptkbp:mechanismOfAction |
mTORC1/2 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
ATG-008
onatasertib |
| gptkbp:target |
gptkb:mTORC1
gptkb:mTORC2 |
| gptkbp:bfsParent |
gptkb:Antengene
|
| gptkbp:bfsLayer |
7
|
| http://www.w3.org/2000/01/rdf-schema#label |
ATG-008 (onatasertib)
|